Aspida Dx

The escalating opioid crisis remains one of the most pressing public health challenges in the United States, with over 75% of drug overdose deaths in recent years involving opioids. As synthetic opioids like fentanyl continue to saturate the illicit market, the need for rapid, adaptable, and precise diagnostic tools has never been greater. Aspida Dx is stepping into this gap with a technology platform designed to transform how we detect and manage substance use.

Revolutionary Saliva-Based Detection
At the core of the Aspida Dx system is an integrated collection device and test cartridge paired with an instrument reader. Unlike traditional laboratory-based screenings that can take days to process, this system can detect the most currently abused drugs from a saliva sample in just 15 minutes.
This speed is a critical advantage in several high-stakes environments:
• Medication-Assisted Treatment (MAT): Physicians will be able use the tool for frequent monitoring to ensure patient compliance with treatment programs and verify they are not taking dangerous substances that could lead to relapse or fatal combinations.
• Legal and Judicial Systems: Courts will be able to utilize the rapid results for individuals whose plea deals or parole are conditioned on addiction treatment compliance.
• Public Safety: Law enforcement agents will gain an advanced tool for assessing subjects for Driving Under the Influence (DUI) or DUID.
Adapting to an Evolving Market
One of the greatest hurdles in the opioid crisis is the "continuous flow" of Novel Psychoactive Substances (NPS) appearing on the street. Drug compositions change rapidly, often outpacing the testing capabilities of standard clinics.
Aspida Dx addresses this through strategic partnerships with the Center for Forensic Science Research & Education (CFSRE) and NMS Labs (both based in Pennsylvania) . By leveraging the NPS Discovery program, which identifies novel compone